Therma Bright Engages Top Virology Research Group to Conduct Further Tests of TherOZap(TM) Technology Against the Zika Virus

Toronto, Ontario--(Newsfile Corp. - October 11, 2018) - Therma Bright Inc. (TSXV: THRM), ('Therma Bright' or the 'Company'), a progressive medical device technology company announces, further to its press release on January 8, 2018 outlining results indicating effectiveness of its TherOZap™ technology at inhibiting the Zika virus, that the Company has engaged a top research laboratory made up of virology experts to further test the TherOZap™ technology against the Zika virus. The research group collaborates with and has access to other virology research experts around the world.

Further to the Company's press release on October 1^st, 2018, the Company has completed several improvements to the TherOZap™ technology prototype including certain advancements to the technology and features that make the prototype easier to use and test by researchers compared to the previous version. The Company expects the receipt of final prototypes over the next 10 days at which time the prototypes will be sent to the researchers to initiate the next round of testing. Testing is expected to last several months.

The Company will follow up with additional testing, providing efficacy of the TherOZap™ technology during the initial tests against the Zika virus, with further in-vitro testing of the Zika virus or other mosquito borne diseases to be followed up by in-vivo testing if warranted.

The Dengue, Zika and West Nile viruses are spread by the same mosquito which is known as the Aedes Aegypti mosquito. The Aedes Aegypti mosquito is known as a prolific daytime biter which often makes it harder for people to protect themselves after an infectious bite. Therma Bright hopes to prove that the TherOZap™ technology will be effective as a second line of defense, after being bitten by a mosquito, against the Zika virus. Once the TherOZap™ technology proves effective, the Company expects to extend the prototype improvements to Therma Bright's final commercial device with an aim to market any claims as a result of successful testing on packaging and marketing material with appropriate regulatory approval.

Mr. Rob Fia, CEO, commented:

'Therma Bright searched diligently and is pleased to have selected this collection of top virology researchers to continue testing our patent pending TherOZap™ technology against the Zika virus. We are excited to report back to our shareholders as testing results are received and we hope to prove the Zika virus is susceptible to die-off with the use of our TherOZap™ technology.'

About Therma Bright Inc.:

Therma Bright is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs.  Clear and healthy skin for all is at the core of the Company's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments.  The Company's breakthrough proprietary technology delivers effective, non-invasive and pain free skin care.

Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). The Company received approval for the above claims from FDA (United States) in 1997.

Therma Bright Inc. trades on the TSXV (TSXV: THRM). For more information visit: www.thermabright.com and www.interceptcoldsores.com
Coming soon: www.coldsores.com

For further information please contact:
Therma Bright Inc.
Rob Fia
CEO
rfia@thermabright.com

FORWARD LOOKING STATEMENTS
Certain statements in this news release constitute 'forward-looking' statements. These statements relate to future events or the Company's future performance and include further testing of the TherOZap™ technology against the Zika virus, product improvements to the TherOZap™ technology and timelines for the receipt of the TherOZap™ technology prototype, all as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. In addition to other risks, the Company may not complete all or any of the transactions as described in this news on the timelines described. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES